Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ephedrine

This article was originally published in The Tan Sheet

Executive Summary

Texas Dept. of Health's enforcement of ephedrine rule, which requires supplement labeling to carry FDA's MedWatch number and warning against sales to persons 17 or younger, commenced Sept. 1, DoH confirms Sept. 6. "Whether or not enforcement will include detaining mislabeled products will be determined on a case-by-case basis," department says. Similar provisions have been added to California bill making its way through state legislature. SB 397 cleared Senate June 7. Amendments added during Assembly Health Committee review restrict ephedrine sales to people over 18 and require MedWatch number on label. Assembly Appropriations Cmte. slated to review bill week of Sept. 10
Advertisement

Related Content

Topics

Advertisement
UsernamePublicRestriction

Register

PS093009

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel